Thierry David
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thierry David has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Natacha Stolowy
Department of Ophthalmology, Centre Hospitalier Universitaire de La Timone, Marseille, France
10 shared publications - Ruben Attia
Department of Ophthalmology, hôpital Nord, AP-HM, chemin des Bourrely, 13015 Marseille, France
8 shared publications D. Denis
6 shared publications- Kevin Mairot
Department of ophthalmology, hôpital Nord, Aix-Marseille university, chemin des Bourrely, 13015 Marseille, France
6 shared publications - R. Fitoussi
Department of Ophthalmology, hôpital Nord, AP-HM, chemin des Bourrely, 13015 Marseille, France
6 shared publications - A. Aulanier
Service d'ophtalmologie, hôpital La Timone, 264, rue Saint-Pierre, 13005 Marseille, France
3 shared publications
Latest Publications
- 23 October 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
Validation of an Angiographic Scoring System for Longitudinal Monitoring of Susac Syndrome: A Standardized Approach
Background: In Susac syndrome, there is no standardized scoring system for the interpretation of fluorescein angiography (FA). The objective of this study was to standardize the angiographic evaluation of these patients by applying an angiographic score validated for uveitis to the specific context of Susac syndrome. Methods: Retrospective analysis of patients diagnosed with Susac syndrome was conducted. Angiograms were evaluated using a structured scoring system based on predefined angiographic features and their localization by retinal quadrants. The presence of these items was summed to generate a total score. Interobserver agreement was assessed between 2 independent graders for the angiographic scoring system. Results: From July 2015 to May 2024, 10 patients (mean age 32 ± 13 years; 60% male) were included. A total of 83 bilateral FA (166 eyes) were analyzed, with each patient undergoing between 2 and 17 examinations (median = 8) over a mean follow-up of 42.6 ± 30.2 months. Arterial leakage was present in 60% of patients, and capillary nonperfusion or arterial occlusion in 70% of patients at first visit. The development of new signs of arterial leakage and/or nonperfusion was documented in 33.13% of follow-up angiograms. Most items showed excellent interobserver agreement, with weighted Cohen kappa values above 0.8, and all but 1 item exceeding 0.7. Conclusions: This angiographic scoring system demonstrates validity and repeatability for assessing Susac syndrome. Further prospective studies are needed to assess its application in larger cohorts, explore treatment response, and evaluate its role in guiding therapy decisions.
- 23 October 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
Validation of an Angiographic Scoring System for Longitudinal Monitoring of Susac Syndrome: A Standardized Approach
Background: In Susac syndrome, there is no standardized scoring system for the interpretation of fluorescein angiography (FA). The objective of this study was to standardize the angiographic evaluation of these patients by applying an angiographic score validated for uveitis to the specific context of Susac syndrome. Methods: Retrospective analysis of patients diagnosed with Susac syndrome was conducted. Angiograms were evaluated using a structured scoring system based on predefined angiographic features and their localization by retinal quadrants. The presence of these items was summed to generate a total score. Interobserver agreement was assessed between 2 independent graders for the angiographic scoring system. Results: From July 2015 to May 2024, 10 patients (mean age 32 ± 13 years; 60% male) were included. A total of 83 bilateral FA (166 eyes) were analyzed, with each patient undergoing between 2 and 17 examinations (median = 8) over a mean follow-up of 42.6 ± 30.2 months. Arterial leakage was present in 60% of patients, and capillary nonperfusion or arterial occlusion in 70% of patients at first visit. The development of new signs of arterial leakage and/or nonperfusion was documented in 33.13% of follow-up angiograms. Most items showed excellent interobserver agreement, with weighted Cohen kappa values above 0.8, and all but 1 item exceeding 0.7. Conclusions: This angiographic scoring system demonstrates validity and repeatability for assessing Susac syndrome. Further prospective studies are needed to assess its application in larger cohorts, explore treatment response, and evaluate its role in guiding therapy decisions.
- 12 October 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (9)
Early ophthalmological phenotype in RNU4-2 spliceosomopathy caused by the recurrent n.64_65insT variant
- 12 October 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (9)
Early ophthalmological phenotype in RNU4-2 spliceosomopathy caused by the recurrent n.64_65insT variant
- 25 September 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (9)
Une transillumination irienne trompeuse : mégalophtalmie antérieure liée à CPAMD8
- 25 September 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (9)
Une transillumination irienne trompeuse : mégalophtalmie antérieure liée à CPAMD8
- 1 July 2026
- Published by AIP Publishing in Review of Scientific Instruments
- Vol. 97 (7)
Fast and compact scatterometer for ex vivo qualification of low-scattering biological samples.
We present the design, calibration, qualification, and application of a fast and compact scatterometer designed for the characterization of ex vivo human corneas. As an alternative to standard qualification processes and in order to meet the current need for improved reliability of graft qualification, this instrument provides a non-invasive, label-free, and contact-free quantitative means of characterizing corneal grafts, based on back-scattered light diffusometry. The instrument is shown to be capable of detecting BRDF (bidirectional reflectance distribution function) variations of 1.4 × 10-4 sr-1 with a detectivity threshold of 2.0 × 10-3 sr-1, with an overall dynamics >27 dB for the total integrated scattering parameter used for graft quality assessment. We also demonstrate the feasibility of integrating this new technique into tissue bank qualification processes through controlled test experiments reported here.
- 1 July 2026
- Published by AIP Publishing in Review of Scientific Instruments
- Vol. 97 (7)
Fast and compact scatterometer for ex vivo qualification of low-scattering biological samples.
We present the design, calibration, qualification, and application of a fast and compact scatterometer designed for the characterization of ex vivo human corneas. As an alternative to standard qualification processes and in order to meet the current need for improved reliability of graft qualification, this instrument provides a non-invasive, label-free, and contact-free quantitative means of characterizing corneal grafts, based on back-scattered light diffusometry. The instrument is shown to be capable of detecting BRDF (bidirectional reflectance distribution function) variations of 1.4 × 10-4 sr-1 with a detectivity threshold of 2.0 × 10-3 sr-1, with an overall dynamics >27 dB for the total integrated scattering parameter used for graft quality assessment. We also demonstrate the feasibility of integrating this new technique into tissue bank qualification processes through controlled test experiments reported here.
- Open Access
- 27 April 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (6) , 104878
Évaluation fonctionnelle des maculopathies et la rétinopathie diabétique par cartographie pupillaire chromatique multifocale
- 27 April 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (6) , 104878
Open AccessÉvaluation fonctionnelle des maculopathies et la rétinopathie diabétique par cartographie pupillaire chromatique multifocale
- 12 March 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (4) , 104745
Intraocular inflammation on orbital MRI
- 12 March 2026
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (4) , 104745
Intraocular inflammation on orbital MRI
- 18 December 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (2)
Syndrome de Marfan néonatal : une urgence vitale derrière un glaucome congénital trompeur
- 18 December 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (2)
Syndrome de Marfan néonatal : une urgence vitale derrière un glaucome congénital trompeur
- 12 December 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (1) , 104728
Herpetic dendritic ulcer resistant to valaciclovir successfully treated with amenamevir
- 12 December 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 49 (1) , 104728
Herpetic dendritic ulcer resistant to valaciclovir successfully treated with amenamevir
- 11 November 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 48 (10) , 104681
Weekly adalimumab: A promising approach for managing refractory non-infectious chronic pediatric uveitis
- 11 November 2025
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 48 (10) , 104681
Weekly adalimumab: A promising approach for managing refractory non-infectious chronic pediatric uveitis
- 1 September 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (2) , 321-329
Short-term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti-VEGF injections : A real-life study
Objective: To evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen. Methods: This retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval. Primary outcomes included changes in subretinal (SRF) and intraretinal fluid (IRF). Results: Among 39 patients (47 eyes), the proportion of eyes with SRF decreased from 43.1% to 23.5% ( p < 0.01) and IRF from 43.8% to 19.6% ( p < 0.01). SRF height significantly reduced from 75.3 μm to 60 μm ( p = 0.04). Pigment epithelial detachment (PED) height decreased from 223 μm to 164μm ( p < 0.01), and central retinal thickness (CRT) declined from 273.7 μm to 268 μm ( p < 0.01). Injection intervals extended by an average of 7 days (40 to 47 days, p < 0.01). No significant changes in BCVA ( p = 0.14) were observed. No adverse events were reported. Conclusions: Switching to faricimab without restarting an induction phase effectively reduces SRF and IRF while modestly extending injection intervals in patients requiring frequent anti-VEGF injections. These findings suggest a potential benefit in treatment burden reduction. Further studies are needed to assess long-term visual outcomes and safety.
- 1 September 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (2) , 321-329
Short-term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti-VEGF injections : A real-life study
Objective: To evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen. Methods: This retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval. Primary outcomes included changes in subretinal (SRF) and intraretinal fluid (IRF). Results: Among 39 patients (47 eyes), the proportion of eyes with SRF decreased from 43.1% to 23.5% ( p < 0.01) and IRF from 43.8% to 19.6% ( p < 0.01). SRF height significantly reduced from 75.3 μm to 60 μm ( p = 0.04). Pigment epithelial detachment (PED) height decreased from 223 μm to 164μm ( p < 0.01), and central retinal thickness (CRT) declined from 273.7 μm to 268 μm ( p < 0.01). Injection intervals extended by an average of 7 days (40 to 47 days, p < 0.01). No significant changes in BCVA ( p = 0.14) were observed. No adverse events were reported. Conclusions: Switching to faricimab without restarting an induction phase effectively reduces SRF and IRF while modestly extending injection intervals in patients requiring frequent anti-VEGF injections. These findings suggest a potential benefit in treatment burden reduction. Further studies are needed to assess long-term visual outcomes and safety.